1541 Background: Prognostic scores are commonly used to guide enrollment in early-phase oncology trials. Despite their widespread use, these models have not been specifically evaluated in Hispanic patients, to the best of our knowledge — a population historically underrepresented in clinical trials. We evaluated the predictive performance of the Royal Marsden Hospital (RMH) score, the Princess Margaret Hospital Index (PMHI), and the MD Anderson Cancer Center (MDACC) score in a cohort of Hispanic patients with advanced solid tumors enrolled in phase I clinical trials. Methods: We performed a retrospective chart review of Hispanic patients with advanced solid tumors enrolled in phase I clinical trials at USC Norris Comprehensive Cancer Center and its affiliated safety-net institution, Los Angeles General Medical Center, between 2015 and 2022. Prognostic scores were calculated using the established criteria: RMH score (albumin ULN, >2 metastatic sites), PMHI (albumin 0, >2 metastatic sites), and MDACC score (albumin ULN, ECOG >0, >2 metastatic sites, gastrointestinal tumor type). RMH and PMHI risk groups were categorized as low (0–1 points) or high (2–3 points), while MDACC risk groups were defined as low (0–1 points), intermediate (2–3 points), or high (4–5 points). Overall survival (OS) was analyzed using Kaplan–Meier methods. Results: A total of 191 Hispanic patients were included (109 gastrointestinal, 36 lung/head and neck, 20 other, 16 gynecologic, 6 genitourinary, 4 breast). Median age was 59 years (25–86). The median OS for this cohort was 13.1 months (95% CI, 8.8-18.3). Significant differences in OS were observed across prognostic risk groups for all three prognostic scores. Median OS for RMH high- versus low-risk patients was 5.1 versus 18.3 months (p=0.004); for PMHI high- versus low-risk patients, 6.5 versus 20.0 months (p=0.002); and for MDACC high-, intermediate-, and low-risk patients, 4.1, 15.7, and 32.7 months, respectively (p=0.007). Conclusions: In this Hispanic solid tumor phase I trial population, higher RMH, PMHI, and MDACC scores were associated with poorer overall survival. These findings support the use of established prognostic scores in Hispanic patients for identifying candidates with poor prognosis and informing early-phase trial enrollment. Prospective studies are warranted to further validate prognostic scores in the Hispanic population. RMH Median OS (Months) PMH Median OS (Months) MDACC Median OS (Months) Low (0-1) 5.1 Low (0-1) 6.5 Low (0-1) 4.1 High (2-3) 18.3 High (2-3) 20.0 Intermediate (2-3) 15.7 High (4-5) 32.7 p=0.004 p=0.002 p=0.007
Poei et al. (Wed,) studied this question.